The goals of this study are the following: (1) To determine the maximum tolerated dose of CPT-11 when administered every 3 weeks to patients with recurrent malignant glioma. (2) To determine toxicities of every three-week dosing. (3) To characterize pharmacokinetics of CPT-11 and its metabolites, SN-38, SN-38 gluconide (SN-38G) and APC. (4) To assess antitumor activity. We wish to use the expertise of the GCRC in drug administration, patient care, and patient teaching to achieve the study goals.
Showing the most recent 10 out of 634 publications